目的 分析外源性肺表面活性物质(PS)对新生儿呼吸窘迫综合征(NRDS)患儿免疫功能的影响,寻找外源性肺表面活性物质的新用途,为新生儿呼吸窘迫综合征防治提供新的理论依据。 方法 选择确诊为新生儿呼吸窘迫综合征的61例患儿为研究对象,以PS替代治疗者(30例)为观察组,未行PS替代治疗者(31例)为对照组,检测两组患儿治疗前后的免疫球蛋白、补体水平及淋巴细胞亚型。 结果 与治疗前比较,观察组NRDS患儿IgG水平降低不明显(P>0.05),而B细胞、NK细胞显著增高(P<0.05),而血清IgA、IgM、补体C3、C4水平及Th、Ts 淋巴细胞在治疗前后比较差异均无统计学意义(P>0.05)。结论 外源性PS可改善NRDS患儿免疫功能,对其提高疗效可能起了一定作用。
Abstract
Objective To investigate the effects of exogenous pulmonary surfactant (PS) on immune function in infants with neonatal respiratory distress syndrome (NRDS),and to explore new usage of exogenous pulmonary surfactant,in order to provide new evidence and theoretical basis for prevention and treatment of neonatal respiratory distress syndrome. Method Totally 61 patients with neonatal respiratory distress syndrome were selected as the research objects. Thirty patients treated with PS were selected as the observation group, while 31 infants received no PS replacement therapy as the control group. The levels of immunoglobulin,complement and lymphocyte subtypes were measured before and after treatment in both groups. Results After treatment,the level of IgG in patients with NRDS in observation group did not significantly decrease(P>0.05),while B lymphocytes and natural killer(NK) cell increased significantly (P<0.05). However,there were no significant difference on serum IgA,IgM,complement C3,C4,Th and Ts leukomonocyte before and after treatment in the two groups(P>0.05). Conclusion Exogenous PS can improve immune function in infant with neonatal respiratory distress syndrome,and it may play a certain role in improving the therapeutic effect.
关键词
外源性肺表面活性物质 /
新生儿呼吸窘迫综合征 /
免疫功能 /
新生儿
Key words
exogenous pulmonary surfactant /
neonatal respiratory distress syndrome /
immune function /
neonates
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Sweet DG,Carnielli V,Greisen G,et al.European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2013 update [J].Neonatology,2013,103(4):353-368.
[2] Wolfson MR,Wu J,Hubert TL,et al.Lucinactant attenuates pulmonary inflammatory response,preserves lung structure,and improves physiologic outcomes in a preterm lamb model of RDS [J].Pediatr Res,2012,72(4):375-383.
[3] 韩笑,尹晓娟.肺表面活性物质蛋白C研究新认识[J].中国儿童保健杂志,2015,23(1):49-51.
[4] Parra E,Pérez-Gil J.Composition,structure and mechanical properties define performance of pulmonary surfactant membranes and films [J].Chem and Phys of Lipids,2015,185: 153-175.
[5] Han SH,Mallampalli RK.The role of surfactant in lung disease and host defense against pulmonary infections [J].Ann Am Thorac Soc,2015,12(5):765-774.
[6] Ariki S,Nishitani C,Kuroki Y.Diverse functions of pulmonary collectins in host defense of the lung[J].J Biomed Biotechnol,2012: 532071.
[7] Gaunsbaek MQ,Rasmussen KJ,Beers MF,et al.Lung surfactant protein D (SP-D) response and regulation during acute and chronic lung injury[J].Lung,2013,191(3): 295-303.
[8] Bersani I,Speer CP,Kunzmann S.Surfactant proteins A and D in pulmonary diseases of preterm infants [J].Expert Rev Anti-Infect ther,2012,10(5): 573-584.
[9] Preuss S,Omam F D,Scheier mann J,et al.Topical application of phosphatidyl-inositol-3,5-bisphosphate for acute lung injury in neonatal swine [J].J Cell Mol Med,2012,16(11): 2813-2826.
[10] 尹晓娟,韩笑,范含笑,等.足月新生儿呼吸窘迫综合征SP-B+1580基因突变分析[J].中国儿童保健杂志,2013,21(7):682-684.
[11] 王成祥,常绍鸿.外源性 PS 应用对早产儿 SP-A,SP-D 的影响[J].医学信息,2013,26(3):170-171.
[12] 连丽丽,孙璐璐,袁野,等.长春市地区儿童血清免疫球蛋白生物参考区间建立[J].中华检验医学杂志,2015,38 (3) :191-195.
基金
吴阶平医学基金会临床科研课题(320.6750.14168)
PDF(482 KB)
